← Eichor
Condition: Acute Myeloid Leukemia Relapsed Adult Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Acute Myeloid Leukemia Relapsed Adult

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase 1 · 1 location(s) · Terrence J Bradley, MD · NCT05597306Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase 1 · 7 location(s) · Nerviano Medical Sciences · NCT06549790Anti-CD33-CLL1 CAR-T Cells (ICG415) for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Phase 1 · 2 location(s) · iCell Gene Therapeutics · NCT07668557Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia
Phase 1 · 1 location(s) · Pacylex Pharmaceuticals · NCT06613217CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relap
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT04375631Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Phase N/A · 5 location(s) · Children's Hospital Medical Center, Cincinnati · NCT06131801A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in
Phase 1 · 2 location(s) · Mayo Clinic · NCT03017820Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in
Phase 2 · 20 location(s) · French Innovative Leukemia Organisation · NCT06022003A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies
Phase 1 · 3 location(s) · Cullgen (Shanghai),Inc · NCT07347171A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT05748197Acute Myeloid Leukemia At Initial Diagnosis and/or Relapse in Children, Teenagers and Young Adults: Molecular Profiling,
Phase N/A · 28 location(s) · Assistance Publique - Hôpitaux de Paris · NCT05772559Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients Wi
Phase 1 · 1 location(s) · BlueSphere Bio, Inc · NCT07566585CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
Phase 2 · 1 location(s) · University of Maryland, Baltimore · NCT04050280Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant
Phase 1/Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT06928662Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
Phase 1 · 1 location(s) · Children's Hospital Medical Center, Cincinnati · NCT03826992Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
Phase 1 · 13 location(s) · Stelexis BioSciences · NCT06533761Personalized NK Cell Therapy in CBT
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT02727803Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07523555Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
NA · 20 location(s) · Massachusetts General Hospital · NCT05237258Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched
Phase 2 · 1 location(s) · University of Illinois at Chicago · NCT06802315Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML
Phase 2 · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT053058593'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT00935090A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
Phase 1 · 13 location(s) · BlossomHill Therapeutics · NCT06501196Venetoclax Basket Trial for High Risk Hematologic Malignancies
Phase 1 · 5 location(s) · Andrew E. Place, MD · NCT05292664A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AML
NA · 1 location(s) · Ruijin Hospital · NCT06329999Novel Digital Application for Patients With Acute Leukemia
NA · 3 location(s) · Massachusetts General Hospital · NCT06472128L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adu
Phase 2/Phase 3 · 25 location(s) · Moleculin Biotech, Inc. · NCT06788756Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell
Phase 2 · 1 location(s) · Federal Research Institute of Pediatric Hematology, Oncology · NCT07256210CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML
Phase 1 · 1 location(s) · University of Colorado, Denver · NCT07347418
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.